Drug2nd line3 diseases
Rilonacept
IL-1 decoy receptor (IL-1 Trap)
- Response rate
- Significant improvement vs placebo
- Onset
- Days–weeks
- Route
- SC 160mg load, then 80mg weekly
- Line
- 2nd
- IgM effect
- Improved
- Evidence level
- amber
- Trial phase
- Phase 4
Used across diseases
| Disease | Response rate | Line | Evidence |
|---|---|---|---|
| Cryopyrin-Associated Periodic Syndromes | Significant improvement vs placebo | 2nd | amber |
| Familial Mediterranean Fever | Moderate | 3rd | amber |
| Schnitzler Syndrome | Limited data | Alternative | default |
Evidence summary
Dimeric fusion protein acting as IL-1 'trap' neutralizing IL-1α and IL-1β. FDA-approved for FCAS and MWS (2008). Two sequential placebo-controlled studies demonstrated efficacy. Less widely used than anakinra/canakinumab due to limited long-term data and availability.
Approved indications
Conditions for which Rilonacept has regulatory approval (not specific to rare diseases covered here):
FCASMWSRecurrent Pericarditis
Drug identifiers
| DrugBank | DB06372 ↗ |
| ATC Code | L04AC04 |
| Open Targets | CHEMBL1201561 ↗ |